Skip to main content

Table 1 Characteristics of the children enrolled in the trial for mefloquine and artesunate/dihydroartemisinin model development, mefloquine model validation and pharmacokinetic-pharmacodynamic analysis

From: Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

Baseline characteristic Model-building dataset (n = 48) MQ validation dataset (n = 378) MQ pharmacokinetic–pharmacodynamic analysis dataset (n = 451)
Value % or range Value % or range Value % or range
Demographic characteristics
 Sex (male/female) (no.) 19/29 40/60 183/195 48/52 219/232 49/51
 Median age (year) 2.6 0.6–5.0 2.3 0.5–5.0 2.4 0.5–5.0
 Median body weight (kg) 12 7–17 11 5–18 11 5–19
 Median height/length (cm) 89 66–114 85 62–114 86 60–114
Physiological characteristics
 Total bilirubin (μmol/L) 10 1–77 10 0.4–74 17 0.5–163
 Serum creatinine (μmol/L) 42 3–119 36 2–86 40 3–120
 Haematocrit (%) 31 17–49 30 16–59 30 17–62
 Haemoglobin (g/dL) 10 5–15 9 5–18 9 5–19
 AST (IU) 39 5–302 34 7–576 39 5–680
 ALT (IU) 19 7–449 16 4–378 18 3–814
Baseline parasite counts (no/μL)
 Median at day 0 58,131 3322–190,896
 Median at day 1 280 0–13,816
 Median at day 2 0 0–100
Co-administered drugs
 CYP3A4 inducers (at least for one drug measurement/never) (no.) 7/41 15/85
  1. AST, aspartate aminotransferase; ALT, alanine aminotransferase